
REPROCELL Files for Japanese Approval of Stemchymal Therapy
With patients suffering from spinocerebellar ataxia facing few viable treatment options, Yokohama-based REPROCELL has officially submitted its application for manufacturing and marketing approval in Japan for Stemchymal. The regenerative medicine product aims to suppress the progression of motor function loss in individuals diagnosed with SCA3 and SCA6.
























